Assessment of the 4Ts pretest clinical scoring system as a predictor of heparin-induced thrombocytopenia

Pharmacotherapy

Volumn 31, Issue 2, 2011, Pages 138-145

  Strutt, Jaclyn K ^a   Mackey, Jennifer E ^b   Johnson, Stephen M ^b   Sylvia, Lynne M ^b  

^a SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

4Ts pretest scoring system; Anticoagulation; ELISA; Enzyme linked immunosorbent assay; Heparin; Heparin induced thrombocytopenia; HIT; Serotonin release assay; SRA; Thrombocytopenia

Indexed keywords

ANTIBODY; ARGATROBAN; COTRIMOXAZOLE; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LINEZOLID; THROMBOCYTE FACTOR 4; VALPROIC ACID; VANCOMYCIN;

4TS CLINICAL SCORING SYSTEM; ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERRATER RELIABILITY; KAPPA STATISTICS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PROBABILITY; PROSPECTIVE STUDY; SCORING SYSTEM; TERTIARY HEALTH CARE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS;

ANTIBODIES; ANTICOAGULANTS; DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PLATELET FACTOR 4; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 79551606959     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.2.138     Document Type: Article

References (28)

1. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest 2008;133:340S-80.
2. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk of heparin-induced thrombocytopenia. Blood 2000;96:1703-8. (Pubitemid 30661052)
3. Haines ST, Racine E, Zoella M. Venous thromboembolism. In: DiPiro JT, ed. Pharmacotherapy: a pathophysiologic approach. New York: McGraw-Hill Companies Inc., 2002:367-9.
4. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb and Haemost 2006;4:759-65.
5. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005;146:341-6.
6. Juhl D, Eichler P, Lubenow N. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006;76:420-6.
7. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007;5:1666-73. (Pubitemid 47091409)
8. Lindhoff-Last E, Eichler P, Stein M, et al. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res 2000;97:387-93. (Pubitemid 30125704)
9. Zwicker JI, Uhl L, Huang W-Y, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin induced thrombocytopenia. J Thromb Haemost 2004;2:2133-7. (Pubitemid 40185772)
10. Warkentin TE. Heparin-induced thrombocytopenia: diagnosis and management. Circulation 2004;110:e454-8.
11. Pouplard C, Gueret P, Fouassier M, et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007;5:1373-9.
12. Crowther MA, Cook DJ, Albert M, et al. The 4Ts scoring system for heparin-induced thrombocytopenia in medicalsurgical intensive care unit patients. J Crit Care 2010;25:287-93.
13. Janatpour KA, Gosselin RC, Dager WE, et al. Usefulness of optical density values from heparin-platelet factor 4 antibody testing and probability scoring models to diagnose heparin-induced thrombocytopenia. Am J Clin Pathol 2007;127:429-33.
14. ECAT Foundation. International external quality assessment programme in haemostasis and thrombosis. Exercise 2009-4. Leiden, The Netherlands: ECAT Foundation, 2009.
15. Wazny LD, Ariano RE. Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy 2000;20:292-307.
16. Shalansky SJ, Verma AK, Levine M, Spinelli JJ, Dodek PM. Risk markers for thrombocytopenia in critically ill patients: a prospective analysis. Pharmacotherapy 2002;22:803-13. (Pubitemid 34743431)
17. Drews RE, Weinberger SE. Thrombocytopenic disorders in critically ill patients. Am J Respir Cit Care Med 2000;162:347-51.
18. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:2121-31.
19. Von Drygalski A, Curtis BR, Bougie DW, et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007;356:904-10.
20. Oppenheimer L, Hrynuik WM, Bishop AJ. Thrombocytopenia in severe bacterial infections. J Surg Res 1976;20:211-14.
21. Vonderheide RH, Thadhani R, Kuter DJ. Association of thrombocytopenia with the use of intra-aortic balloon pumps. Am J Med 1998;105:27-32. (Pubitemid 28346106)
22. Yamreudeewong W, Fosnocht BJ, Weixelman JM. Severe thrombocytopenia possibly associated with TMP/SMX therapy. Ann Pharmacother 2002;36:78-82. (Pubitemid 34052950)
23. Kaufman DW, Kelly JP, Johannes CB, el al. Acute thrombocytopenic purpura in relation to use of drugs. Blood 1993;82:2714-18.
24. Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 2003;37:517-20.
25. Carney R, Nasreddine W, Drury I, et al. Relation between thrombocytopenia and valproate dose [abstract]. Epilepsia 1997;38(suppl 8):102.
26. Hongo RH, Brent BN. Association of eptifibatide and acute profound thrombocytopenia. Am J Cardiol 2001;88:428-31.
27. Nagge J, Jackevicius C, Dzavik V, Ross JR, Seidelin P. Acute profound thrombocytopenia associated with eptifibatide therapy. Pharmacotherapy 2003;23:374-9. (Pubitemid 36259342)
28. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001;135:502-6.